Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD),
